Southfield Capital Acquires BioPharm Communications in Partnership with Management
March 28, 2012
Greenwich, CT - Southfield Capital, a private investment firm focused on the lower middle-market, announced today that it has acquired majority ownership of BioPharm Communications. BioPharm is a leading medical communications and marketing agency that specializes in providing non-personal, peer-to-peer solutions to the pharmaceutical and biotechnology industries. BioPharm’s senior management will continue in their current operating roles and will maintain a minority ownership position in the company. Additional terms of the transaction were not disclosed.

Headquartered in New Hope, PA, BioPharm develops promotional medical education programs for customers in the pharmaceutical and biotechnology industries. The company creates robust clinical content in collaboration with key opinion leaders and delivers it to healthcare practitioners through the company’s comprehensive suite of proprietary branded programs. BioPharm maximizes on-line and off- line clinician engagements via its multi-channel “surround sound” delivery capabilities, including targeted direct mail, e-mail, web hosting, web banners/display advertising, search engine marketing, DVDs, mobile devices, selling kits, e-meetings and teleconferences. BioPharm leverages its experienced account managers, streamlined processes and extensive content development expertise across numerous therapeutic classes to deliver campaigns that generate industry leading engagements and returns on investment.

“The BioPharm team is very excited about our partnership with Southfield Capital,” said Jeff Persinger, co-founder and CEO of BioPharm. “We selected Southfield because of their collaborative management philosophy and proven track record of assisting lower middle-market companies achieve explosive growth. Their dedication to learning our business and understanding the industry was truly impressive. We are confident that Southfield is the right partner to help us develop and execute on a successful organic and acquisition growth strategy.”

Southfield Capital Operating Partner, Vince Tyra, commented, “We are very pleased to announce this investment in BioPharm. Jeff Persinger and Daniel Egeland have built an extraordinary business and have surrounded themselves with highly talented and motivated people. Healthcare reform is making it more and more difficult for brands to utilize the traditional sales representative model, and we believe BioPharm is well-positioned to capitalize on the expected growth in the non-personal healthcare marketing industry.”

Abacus Finance Group provided the senior debt financing, and Boathouse Capital and CMS Mezzanine provided the subordinated debt financing. Finn Dixon & Herling provided legal counsel to Southfield Capital. Grant Thornton Corporate Finance acted as financial advisor to BioPharm and its shareholders.

About Southfield Capital
Southfield Capital is a private equity firm that invests in exceptional, growing companies in the lower middle market. The firm makes control investments in North American companies generating $4 - 12 million in EBITDA with proven business models, attractive growth and profitability trends, and strong leadership. For more information, please visit

Heb James, Partner
Southfield Capital
(203) 813-4113